|
Hans Georg Rammensee
Hans-Georg Rammensee (born 12 April 1953) is a German immunologist and cancer researcher. He has been Chair Professor and Head of the Department of Immunology at the University of Tübingen since 1996. Rammensee has contributed essentially to the research fields of MHC biology and tumor immunology and to the development of cancer immunotherapies. Life Rammensee studied Biology at the University of Tübingen and worked as a PhD student at the Max Planck Institute for Biology in Tübingen. After gaining his doctorate in 1982 he initially worked as a post-doctoral research fellow at Scripps Research Institute, La Jolla, USA. In 1985 he moved as a scientific member to the Basel Institute for Immunology, Basel, Switzerland. Two years later Rammensee returned to Max Planck Institute for Biology as a group leader at the department of immunogenetics. 1993 he became head of department at the Tumor-Virus-Immunology Section of the German Cancer Research Center, Heidelberg, Germany. The sa ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
H Antigen
H antigen can refer to one of various types of antigens having diverse biological functions. H antigen is located on the 19th chromosome in humans, and has a variety of functions and definitions as follows: * Also known as substance H, H antigen is a precursor to each of the ABO blood group antigens, apparently present in all people except those with the Bombay Blood phenotype (see hh blood group) * Histocompatibility antigen, a major factor in graft rejection. Even when Major Histocompatibility Complex genotype is perfectly matched, can cause slow rejection of a graft. ** major H antigens "encode molecules that present foreign peptides to T cells" ** minor H antigens "present polymorphic self peptides to T cells". Includes, e.g. the H-Y antigen H-Y antigen is a male tissue specific antigen. Originally thought to trigger the formation of testes (via loci, an autosomal gene that generates the antigen and one that generates the receptor) it is now known that it does not tri ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cornelis Melief
Cornelis Joseph Maria Melief (born 20 January 1943) is a Dutch immunologuist specialising in cancer immunology and immunotherapy, with a focus on therapeutic cancer vaccines. He is emeritus Professor, former head of the Department of Immunohematology and Blood Transfusion at the Leiden University Medical Center, and Chief Scientific Officer at ISA Therapeutics in Netherlands. He is known for his work in the field of cancer immunology, devising new cancer therapies based on the activation of the patient's own immune system. Early life and education He grew up in the South of the Netherlands, in the town of and from 11 years of age onwards in Amsterdam. He received his PhD Doctorate in Medicine in 1967 from the University of Amsterdam, followed by a Medical Doctor degree in 1970 from the same university. In 1973 and 1974 he was a postdoctoral fellow at the New England Medical Center and Dana-Farber Cancer Institute in Boston. From 1970 to 1972, Melief served as an MD Lieutenant ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Heinz Maier Leibnitz Prize
The Heinz Maier-Leibnitz-Preis (Heinz Maier-Leibnitz Prize), in honor and memory of the German physicist Heinz Maier-Leibnitz, is funded by the ''Bundesministerium für Bildung und Forschung'' (BMBF, German Ministry of Education and Research), and it is awarded by a selection committee appointed by the ''Deutsche Forschungsgemeinschaft'' (DFG, German Research Foundation) and the BMBF. Since 2013, there are ten recipients of the prize and each receives 20,000 Euros, which is an increase over the original 16,000 Euros that had been given to six recipients per year until 2012. Nominees for the award may be put forward by: *Members of the DFG Review Boards *Research universities of the Federal Republic of Germany *The ''Union der deutschen Akademien der Wissenschaften'' (Union of the German Academies of Sciences and Humanities)Union der deutschen Akademien der Wissenschaften' *The Max Planck Society *The Helmholtz Association of German Research Centres *The Fraunhofer Society *The Got ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Gottfried Wilhelm Leibniz Prize
The Gottfried Wilhelm Leibniz Prize (german: link=no, Förderpreis für deutsche Wissenschaftler im Gottfried Wilhelm Leibniz-Programm der Deutschen Forschungsgemeinschaft), in short Leibniz Prize, is awarded by the German Research Foundation to "exceptional scientists and academics for their outstanding achievements in the field of research". Since 1986, up to ten prizes are awarded annually to individuals or research groups working at a research institution in Germany or at a German research institution abroad. It is considered the most important research award in Germany. The prize is named after the German polymath and philosopher Gottfried Wilhelm Leibniz (1646–1716). It is one of the highest endowed research prizes in Germany with a maximum of €2.5 million per award. Past prize winners include Stefan Hell (2008), Gerd Faltings (1996), Peter Gruss (1994), Svante Pääbo (1992), Theodor W. Hänsch (1989), Erwin Neher (1987), Bert Sakmann (1987), Jürgen Habermas (1986), ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Robert Koch Prize
The Robert Koch Medal and Award are two prizes awarded annually by the German for excellence in the biomedical sciences. These awards grew out of early attempts by German physician Robert Koch to generate funding to support his research into the cause and cure for tuberculosis. Koch discovered the bacteria (''Mycobacterium tuberculosis'') responsible for the dreaded disease and rapidly acquired international support, including 500,000 gold marks from the Scottish-American philanthropist Andrew Carnegie. The Robert Koch Prize Since 1970, the Robert Koch Foundation has awarded prizes for major advances in the biomedical sciences, particularly in the fields of microbiology and immunology. The prestige of this award has grown over the past decades so that it is now widely regarded as the leading international scientific prize in microbiology. As has been described by a jury member for the prize, the committee often asks, "What would Robert Koch work on today?” to decide on resea ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Paul Ehrlich And Ludwig Darmstaedter Prize
The Paul Ehrlich and Ludwig Darmstaedter Prize is an annual award bestowed by the since 1952 for investigations in medicine. It carries a prize money of 120,000 Euro. The prize awarding ceremony is traditionally held on March 14, the birthday of Nobel laureate Paul Ehrlich, in the St. Paul's Church, Frankfurt am Main. Researchers from worldwide are awarded in the following fields of medicine: Immunology, Cancer research, Haematology, Microbiology and experimental and clinical Chemotherapy. It is one of the highest endowed and internationally most distinguished awards in medicine in Germany. Some of the prize winners were later awarded the Nobel Prize. List of winners * 1952 ** , Tübingen ** , Nonnenhorn * 1953 ** Adolf Butenandt, Munich * 1954 ** Ernst Boris Chain, London * 1956 ** Gerhard Domagk, Elberfeld * 1958 ** Richard Johann Kuhn, Heidelberg * 1960 ** Felix Haurowitz, Bloomington * 1961 ** Albert Hewett Coons, Boston ** , Langen ** Örjan Ouchterlony, Gothenburg * ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
European Research Council
The European Research Council (ERC) is a public body for funding of scientific and technological research conducted within the European Union (EU). Established by the European Commission in 2007, the ERC is composed of an independent Scientific Council, its governing body consisting of distinguished researchers, and an Executive Agency, in charge of the implementation. It forms part of the framework programme of the union dedicated to research and innovation, Horizon 2020, preceded by the Seventh Research Framework Programme (FP7). The ERC budget is over €13 billion from 2014 – 2020 and comes from the Horizon 2020 programme, a part of the European Union's budget. Under Horizon 2020 it is estimated that around 7,000 ERC grantees will be funded and 42,000 team members supported, including 11,000 doctoral students and almost 16,000 post-doctoral researchers. Researchers from any field can compete for the grants that support pioneering projects. The ERC competitions are open ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ernst Jung Prize
The Ernst Jung Prize is a prize awarded annually for excellence in biomedical sciences. The Ernst Jung Foundation, funded by Hamburg merchant Ernst Jung in 1967, has awarded the Ernst Jung Prize in Medicine, now €300,000, since 1976, and the lifetime achievement Ernst Jung Gold Medal for Medicine since 1990. Ernst Jung Prize for Medicine SourceJung Foundation *1976: Donald Henderson and Lorenz Zimmerman *1977: and John B. West *1979: Karl Lennert and *1980: , Alan Parks and *1981: David E. Kuhl *1982: Hartmut Wekerle and Rolf M. Zinkernagel *1983: and Richard Lower *1984: , Werner Franke and Klaus Weber *1985: Hendrik Coenraad Hemker, Rudolf Pichlmayr and Peter K. Vogt *1986: Albrecht Fleckenstein *1987: Peter Richardson and *1988: Helmut Sies and Charles Weissmann *1989: and Jon van Rood *1990: Gerhard Giebisch and *1991: David Ho and *1992: Roy Yorke Calne and *1993: Charles A. Dinarello and Robert Machemer *1994: and Wolf Singer *1995: Anthony Fauci and ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Recombinant Antibodies
Recombinant antibodies are antibody fragments produced by using recombinant antibody coding genes. They mostly consist of a heavy and light chain of the variable region of immunoglobulin. Recombinant antibodies have many advantages in both medical and research applications, which make them a popular subject of exploration and new production against specific targets. The most commonly used form is the single chain variable fragment (scFv), which has shown the most promising traits exploitable in human medicine and research. In contrast to monoclonal antibodies produced by hybridoma technology, which may lose the capacity to produce the desired antibody over time or the antibody may undergo unwanted changes, which affect its functionality, recombinant antibodies produced in phage display maintain high standard of specificity and low immunogenicity. Structure and characterization Formats There are several known formats of recombinant antibodies which are commonly produced. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Messenger RNA
In molecular biology, messenger ribonucleic acid (mRNA) is a single-stranded molecule of RNA that corresponds to the genetic sequence of a gene, and is read by a ribosome in the process of synthesizing a protein. mRNA is created during the process of transcription, where an enzyme (RNA polymerase) converts the gene into primary transcript mRNA (also known as pre-mRNA). This pre-mRNA usually still contains introns, regions that will not go on to code for the final amino acid sequence. These are removed in the process of RNA splicing, leaving only exons, regions that will encode the protein. This exon sequence constitutes mature mRNA. Mature mRNA is then read by the ribosome, and, utilising amino acids carried by transfer RNA (tRNA), the ribosome creates the protein. This process is known as translation. All of these processes form part of the central dogma of molecular biology, which describes the flow of genetic information in a biological system. As in DNA, genetic inf ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
CureVac
CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018. At the beginning of the COVID-19 pandemic, CureVac was considered a beacon of hope for the development of a German vaccine. The federal government invested 300 million euros in the company. First, the CureVac vaccine was delayed due to minor problems, while the previously unknown BioNTech developed with Pfizer the very effective BNT162b2. In mid-2021, however, it became clear that the CureVac-vaccine was only 47 percent effective and is far away from approval. The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
